Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery
ConclusionLiraglutide 3.0 mg, with lifestyle management, reduced weight and improved glycaemic control. These results support liraglutide’s application in certain high-risk populations, including patients waiting for bariatric surgical intervention.
Source: Obesity Surgery - Category: Surgery Source Type: research
More News: Bariatric Surgery | Diabetes | Eating Disorders & Weight Management | Endocrinology | Obesity | Statistics | Surgery | Victoza | Weight Loss